Onkológia 6/2016

Review of of pharmacotherapy of metastatic melanoma

More detailed knowledge of carcinogenesis process in the pathogenesis od melanoma facilitated the developpement of new drugs, moving the treatment efficacy at significantly higher level. Modern molecules approved for the treatment of melanoma can be divided to three groups: inhibitors of intracellular signaling pathways, immunotherapeutics and oncolytic therapy. Author present the summary of efficacy and safety of currently approved drugs (BRAF and MEK inhibitors, CTLA-4 antagonists and PD-1 antagonists, oncolytic therapy) in monotherapy and in combination. Obstacles of new remedies, as toxicity and induction of drug resistence are discussed.

Keywords: melanoma, ipilimumab, vemurafenib, dabrafenib, trametinib, cobimetinib, pembrolizumab, nivolumab, talimogen laherparepvec